Who are Ambrisentan plus Spironolactone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ambrisentan-plus-spironolactone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ambrisentan plus Spironolactone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ambrisentan plus Spironolactone (Ambrisentan plus Spironolactone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Endothelin receptor antagonist + Mineralocorticoid receptor antagonist combination. Area: Cardiovascular.

marketed Endothelin receptor antagonist + Mineralocorticoid receptor antagonist combination Endothelin-1 receptor (ETA/ETB) + Mineralocorticoid receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ambrisentan plus Spironolactone (Ambrisentan plus Spironolactone) — Brigham and Women's Hospital. Ambrisentan blocks endothelin-1 receptors to reduce pulmonary vascular resistance, while spironolactone is a mineralocorticoid receptor antagonist that provides additional hemodynamic and anti-fibrotic benefits.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ambrisentan plus Spironolactone TARGET	Ambrisentan plus Spironolactone	Brigham and Women's Hospital	marketed	Endothelin receptor antagonist + Mineralocorticoid receptor antagonist combination	Endothelin-1 receptor (ETA/ETB) + Mineralocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Endothelin receptor antagonist + Mineralocorticoid receptor antagonist combination class)

Brigham and Women's Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ambrisentan plus Spironolactone — Competitive Intelligence Brief. https://druglandscape.com/ci/ambrisentan-plus-spironolactone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab